$69.97
In chiusura: Oct 10, 6:56 PM EDT
$69.41
-0.56-0.80%
After hour: Oct 10, 6:56 PM EDT
Comments
Loading...
Attività di insider trading
Tieni traccia delle ultime attività di insider trading Ionis Pharmaceuticals. Rimani informato sui recenti acquisti, vendite e impatto sul mercato per le azioni Ionis Pharmaceuticals.
Cos'è l'attività interna?
L'attività di insider trading coinvolge soggetti interni all'azienda, come dirigenti, direttori e dipendenti, impegnati in transazioni sulle azioni della propria azienda. Le transazioni di acquisto e vendita degli addetti ai lavori forniscono informazioni preziose sulla loro fiducia nelle prestazioni future dell'azienda.
Cosa stanno facendo gli Ionis Pharmaceuticals Inc addetti ai lavori?
A Ionis Pharmaceuticals Inc, la recente attività interna ha attirato l'attenzione. Negli ultimi 30 giorni, gli addetti ai lavori hanno riferito di aver venduto un totale di 28.95K azioni del valore di $2.11M, nel frattempo, gli addetti ai lavori hanno segnalare nessun acquisto negli ultimi 30 giorni.
Notevoli acquisti e vendite recenti di insider
- Il giorno ottobre 8, 2025, Brett P Monia, l'azienda CHIEF EXECUTIVE OFFICER sold 437 condivisioni per $69.26 ciascuna.
- Il giorno agosto 26, 2025, Allene M Diaz, l'azienda DIRECTOR sold 1.43K condivisioni per $42.53 ciascuna.
- Il giorno ottobre 8, 2025, Joseph Baroldi, l'azienda EVP, CHIEF BUSINESS OFFICER sold 1.63K condivisioni per $69.37 ciascuna.
Statistiche sulla proprietà per Ionis Pharmaceuticals Inc
Numero di azioni emesse
159.391M
Azioni possedute dagli insider
1.480M
Percentuale posseduta dagli Insider
0.93%
Azioni possedute dagli investitori istituzionali
135.718M
Percentuale posseduta dagli investitori istituzionali
85.1%
Oct 08, 2025 | EVP RESEARCH | -6.85K | $69.02 | -$472.72K | SELL | -18.27% | 30.64K | Oct 06 | ||
Oct 08, 2025 | EVP CLO & GENERAL COUNSEL | -3.24K | $61.30 | -$398.06K | SELL | -5.67% | 53.89K | Oct 06 | ||
Oct 08, 2025 | CHIEF EXECUTIVE OFFICER | -437.00 | $69.26 | -$30.27K | SELL | -0.24% | 179.57K | Oct 06 | ||
Oct 08, 2025 | EVP, CHIEF BUSINESS OFFICER | -1.63K | $69.37 | -$112.73K | SELL | -4.64% | 33.37K | Oct 06 | ||
Oct 02, 2025 | DIRECTOR | -16.80K | $65.50 | -$1.10M | SELL | -15.44% | 92.03K | Oct 01 | ||
Oct 02, 2025 | EVP RESEARCH | 0.00 | $59.96 | -$335.82K | SELL-OPTIONS | 0.00% | 37.49K | Oct 01 - Oct 02 | ||
Oct 02, 2025 | EVP CLO & GENERAL COUNSEL | 0.00 | $63.33 | -$563.80K | SELL-OPTIONS | 0.00% | 57.13K | Oct 02 | ||
Oct 02, 2025 | EVP, CHIEF BUSINESS OFFICER | 0.00 | $49.91 | -$543.21K | SELL-OPTIONS | 0.00% | 35.00K | Oct 02 | ||
Oct 01, 2025 | EVP CLO & GENERAL COUNSEL | 0.00 | $60.70 | -$198.39K | SELL-OPTIONS | 0.00% | 57.13K | Sep 29 - Sep 30 | ||
Oct 01, 2025 | EVP, CHIEF DEVELOPMENT OFFICER | 0.00 | $59.51 | -$664.39K | SELL-OPTIONS | 0.00% | 79.66K | Sep 30 | ||
Oct 01, 2025 | EVP, FINANCE & CFO | 0.00 | $59.51 | -$571.99K | SELL-OPTIONS | 0.00% | 110.50K | Sep 30 | ||
Sep 16, 2025 | EVP CLO & GENERAL COUNSEL | 0.00 | $60.68 | -$13.26K | SELL-OPTIONS | 0.00% | 57.13K | Sep 12 | ||
Sep 11, 2025 | EVP, CHIEF BUSINESS OFFICER | 0.00 | $46.98 | -$362.83K | SELL-OPTIONS | 0.00% | 35.00K | Sep 09 | ||
Sep 11, 2025 | EVP CLO & GENERAL COUNSEL | 0.00 | $62.62 | -$81.08K | SELL-OPTIONS | 0.00% | 57.13K | Sep 09 | ||
Sep 09, 2025 | EVP, CHIEF BUSINESS OFFICER | 0.00 | $46.90 | -$7.55K | SELL-OPTIONS | 0.00% | 35.00K | Sep 05 | ||
Sep 09, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -6.00K | $59.60 | -$357.58K | SELL | -6.77% | 82.68K | Sep 05 | ||
Sep 04, 2025 | EVP RESEARCH | -11.13K | $49.67 | -$552.86K | SELL | -22.89% | 37.49K | Sep 02 | ||
Sep 04, 2025 | DIRECTOR | -28.00K | $57.58 | -$1.61M | SELL | -20.46% | 108.83K | Sep 02 - Sep 03 | ||
Sep 04, 2025 | DIRECTOR | -20.00K | $50.91 | -$1.02M | SELL | -23.16% | 66.34K | Sep 02 | ||
Sep 04, 2025 | CHIEF EXECUTIVE OFFICER | 0.00 | $52.32 | -$3.26M | SELL-OPTIONS | 0.00% | 180.01K | Sep 03 | ||
Sep 04, 2025 | DIRECTOR | 0.00 | $60.00 | -$1.68M | SELL-OPTIONS | 0.00% | 100.00 | Sep 03 | ||
Sep 04, 2025 | DIRECTOR | 0.00 | $60.00 | -$1.68M | SELL-OPTIONS | 0.00% | 100.00 | Sep 03 | ||
Sep 04, 2025 | EVP, CHIEF DEVELOPMENT OFFICER | -10.00K | $50.37 | -$503.67K | SELL | -11.15% | 79.66K | Sep 02 | ||
Sep 04, 2025 | EVP, CHIEF HUMAN RESOURCES OFC | 0.00 | $48.57 | -$78.74K | SELL-OPTIONS | 0.00% | 15.94K | Sep 03 | ||
Sep 04, 2025 | DIRECTOR | -28.00K | $57.58 | -$1.61M | SELL | -20.46% | 108.83K | Sep 02 - Sep 03 | ||
Sep 04, 2025 | EVP, CHIEF BUSINESS OFFICER | 0.00 | $45.57 | -$903.18K | SELL-OPTIONS | 0.00% | 35.00K | Sep 03 | ||
Sep 04, 2025 | EVP CLO & GENERAL COUNSEL | 0.00 | $52.57 | -$1.34M | SELL-OPTIONS | 0.00% | 57.13K | Sep 02 - Sep 03 | ||
Sep 04, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | -5.00K | $56.75 | -$577.62K | SELL | -5.34% | 88.68K | Sep 02 - Sep 03 | ||
Sep 04, 2025 | DIRECTOR | 0.00 | $42.28 | -$571.65K | SELL-OPTIONS | 0.00% | 36.33K | Sep 03 | ||
Sep 04, 2025 | EVP, CHF CLINICAL DEVELOP OFCR | 0.00 | $57.29 | -$138.41K | SELL-OPTIONS | 0.00% | 51.51K | Sep 03 | ||
Aug 26, 2025 | DIRECTOR | -1.43K | $42.53 | -$60.69K | SELL | -7.21% | 18.37K | Aug 22 | ||
Aug 20, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | 0.00 | $38.29 | -$113.78K | SELL-OPTIONS | 0.00% | 93.47K | Aug 18 | ||
Aug 08, 2025 | DIRECTOR | -5.00K | $41.93 | -$209.65K | SELL | -5.47% | 86.34K | Aug 06 | ||
Aug 06, 2025 | EVP, CHIEF DEVELOPMENT OFFICER | -10.00K | $42.86 | -$428.59K | SELL | -10.05% | 89.49K | Aug 05 | ||
Aug 05, 2025 | EVP, CHF CLINICAL DEVELOP OFCR | -9.55K | $42.80 | -$408.70K | SELL | -15.64% | 51.51K | Aug 04 | ||
Aug 01, 2025 | CHIEF EXECUTIVE OFFICER | 0.00 | $38.80 | -$30.16K | SELL-OPTIONS | 0.00% | 179.82K | Jul 30 | ||
Jul 15, 2025 | CHIEF EXECUTIVE OFFICER | -1.16K | $41.74 | -$48.42K | SELL | -0.64% | 179.82K | Jul 11 | ||
May 02, 2025 | DIRECTOR | 15.00K | $31.86 | $477.90K | BUY | 40.30% | 52.22K | May 01 | ||
Apr 17, 2025 | EVP, CORP AND DEVELOPMENT OPS | 1.20K | $28.37 | -$19.29K | SELL-OPTIONS | 2.15% | 56.66K | Apr 15 - Apr 16 | ||
Apr 17, 2025 | EVP, CHF GL PDT STR OFCR | 9.21K | $28.36 | -$85.53K | SELL-OPTIONS | 463.05% | 11.20K | Apr 15 - Apr 16 | ||
Apr 17, 2025 | EVP, CHIEF BUSINESS OFFICER | 6.91K | $28.40 | -$111.56K | SELL-OPTIONS | 24.60% | 35.00K | Apr 15 - Apr 16 | ||
Mar 13, 2025 | CHIEF EXECUTIVE OFFICER | -140.00 | $32.32 | -$4.52K | SELL | -0.08% | 180.98K | Mar 11 | ||
Feb 24, 2025 | EVP CLO & GENERAL COUNSEL | -1.21K | $32.35 | -$39.05K | SELL | -2.10% | 56.24K | Feb 20 | ||
Feb 06, 2025 | EVP CLO & GENERAL COUNSEL | -6.17K | $31.62 | -$194.94K | SELL | -9.69% | 57.45K | Feb 04 | ||
Feb 06, 2025 | CHIEF EXECUTIVE OFFICER | -38.84K | $31.65 | -$1.23M | SELL | -17.69% | 180.68K | Feb 04 | ||
Feb 03, 2025 | EVP RESEARCH | 2.35K | $32.31 | -$44.16K | GRANT | 5.12% | 48.20K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | EVP, CHF CLINICAL DEVELOP OFCR | 2.55K | $32.20 | -$47.78K | GRANT | 4.35% | 61.06K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | EVP CLO & GENERAL COUNSEL | 2.41K | $32.49 | -$45.68K | GRANT | 3.94% | 63.62K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | CHIEF EXECUTIVE OFFICER | 12.13K | $32.45 | -$429.66K | GRANT | 5.85% | 219.53K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | EVP, FINANCE & CFO | 2.62K | $32.44 | -$49.40K | GRANT | 2.42% | 110.50K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | EVP, CHIEF DEVELOPMENT OFFICER | 2.41K | $32.40 | -$45.56K | GRANT | 2.50% | 99.08K | Jan 30 - Jan 31 | ||
Feb 03, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | 2.28K | $32.46 | -$43.08K | GRANT | 2.51% | 93.15K | Jan 30 - Jan 31 | ||
Jan 17, 2025 | EVP RESEARCH | 11.98K | $32.84 | -$235.68K | SELL-OPTIONS | ∞ | 184.00 | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CHF CLINICAL DEVELOP OFCR | 10.85K | $32.79 | -$213.89K | SELL-OPTIONS | 22.76% | 58.51K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP CLO & GENERAL COUNSEL | 12.33K | $32.83 | -$241.63K | SELL-OPTIONS | 25.23% | 61.20K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | CHIEF EXECUTIVE OFFICER | 40.00K | $32.63 | -$1.09M | SELL-OPTIONS | 23.90% | 207.40K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, FINANCE & CFO | 15.02K | $32.81 | -$290.99K | SELL-OPTIONS | 16.17% | 107.89K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CHIEF DEVELOPMENT OFFICER | 11.83K | $32.86 | -$232.41K | SELL-OPTIONS | 13.94% | 96.66K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CHIEF HUMAN RESOURCES OFC | 8.03K | $32.78 | -$139.86K | SELL-OPTIONS | 101.50% | 15.94K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CORP AND DEVELOPMENT OPS | 8.88K | $32.70 | -$176.58K | SELL-OPTIONS | 19.24% | 55.05K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CHIEF SCIENTIFIC OFFICER | 11.26K | $32.90 | -$222.11K | SELL-OPTIONS | 14.14% | 90.87K | Jan 15 - Jan 16 | ||
Jan 17, 2025 | EVP, CHIEF BUSINESS OFFICER | 6.82K | $32.70 | -$144.86K | SELL-OPTIONS | ∞ | 3.07K | Jan 15 - Jan 16 | ||
Dec 26, 2024 | DIRECTOR | 5.00K | $36.22 | $181.08K | BUY | 15.52% | 37.22K | Dec 23 | ||
Nov 14, 2024 | EVP RESEARCH | -1.19K | $37.92 | -$45.28K | SELL | -3.41% | 33.87K | Nov 12 | ||
Nov 14, 2024 | CHIEF EXECUTIVE OFFICER | -6.63K | $38.05 | -$252.29K | SELL | -3.81% | 167.39K | Nov 12 | ||
Nov 14, 2024 | DIRECTOR | -13.51K | $37.86 | -$511.43K | SELL | -29.52% | 32.25K | Nov 12 | ||
Oct 17, 2024 | EVP RESEARCH | 72.00 | $38.31 | -$2.03K | SELL-OPTIONS | 0.21% | 35.06K | Oct 15 - Oct 16 | ||
Sep 03, 2024 | EVP, CHIEF DEVELOPMENT OFFICER | -651.00 | $49.40 | -$32.16K | SELL | -0.76% | 84.82K | Aug 28 - Aug 29 | ||
Aug 06, 2024 | EVP, CHIEF DEVELOPMENT OFFICER | -2.43K | $48.00 | -$116.64K | SELL | -2.76% | 85.51K | Aug 05 | ||
Jul 17, 2024 | DIRECTOR | 0.00 | $37.21 | -$306.96K | SELL-OPTIONS | 0.00% | 100.00 | Jul 16 | ||
Jul 17, 2024 | DIRECTOR | 3.04K | $49.49 | -$81.02K | SELL-OPTIONS | 23.98% | 15.72K | Jul 15 - Jul 16 | ||
Jun 20, 2024 | DIRECTOR | 0.00 | $37.91 | -$76.16K | SELL-OPTIONS | 0.00% | 147.33K | Jun 17 | ||
May 07, 2024 | DIRECTOR | -6.00K | $42.71 | -$256.28K | SELL | -98.36% | 100.00 | May 03 | ||
Apr 17, 2024 | EVP, CHIEF BUSINESS OFFICER | 6.83K | $41.60 | -$166.64K | SELL-OPTIONS | 47.32% | 21.27K | Apr 15 - Apr 16 | ||
Apr 17, 2024 | EVP, CORP AND DEVELOPMENT OPS | 970.00 | $41.66 | -$37.70K | SELL-OPTIONS | 2.15% | 46.16K | Apr 15 - Apr 16 | ||
Feb 16, 2024 | CHIEF EXECUTIVE OFFICER | -387.00 | $44.49 | -$17.22K | SELL | -0.22% | 173.75K | Feb 16 | ||
Feb 02, 2024 | EVP RESEARCH | -8.96K | $51.63 | -$654.71K | SELL | -20.67% | 34.41K | Jan 31 - Feb 02 | ||
Feb 02, 2024 | EVP, CHF CLINICAL DEVELOP OFCR | 1.96K | $49.59 | -$102.70K | GRANT | 4.10% | 49.81K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | EVP CLO & GENERAL COUNSEL | 1.86K | $49.67 | -$97.41K | GRANT | 3.97% | 48.66K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | CHIEF EXECUTIVE OFFICER | 22.29K | $49.37 | -$1.16M | GRANT | 14.68% | 174.14K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | EVP, FINANCE & CFO | 2.02K | $49.54 | -$105.27K | GRANT | 2.22% | 92.91K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | EVP, CHIEF DEVELOPMENT OFFICER | 1.86K | $50.04 | -$98.13K | GRANT | 2.17% | 87.33K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | EVP, CHF GL PDT STR & OPER OFC | 2.02K | $49.60 | -$105.40K | GRANT | 5.96% | 35.83K | Feb 01 - Feb 02 | ||
Feb 02, 2024 | EVP, CHIEF SCIENTIFIC OFFICER | 1.76K | $49.52 | -$91.75K | GRANT | 2.27% | 79.08K | Feb 01 - Feb 02 | ||
Jan 29, 2024 | CHIEF EXECUTIVE OFFICER | -2.29K | $51.75 | -$118.25K | SELL | -1.48% | 151.85K | Jan 25 | ||
Jan 29, 2024 | EVP CLO & GENERAL COUNSEL | -6.45K | $51.75 | -$333.79K | SELL | -12.11% | 46.80K | Jan 25 | ||
Jan 18, 2024 | EVP, CHF GL PDT STR & OPER OFC | 9.50K | $50.42 | -$280.52K | SELL-OPTIONS | 39.07% | 33.81K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP CLO & GENERAL COUNSEL | 12.90K | $50.42 | -$390.43K | SELL-OPTIONS | 31.96% | 53.25K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, CORP AND DEVELOPMENT OPS | 7.58K | $50.42 | -$226.73K | SELL-OPTIONS | 20.50% | 44.58K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP RESEARCH | 10.79K | $50.42 | -$317.88K | SELL-OPTIONS | ∞ | 85.00 | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, CHF CLINICAL DEVELOP OFCR | 9.68K | $50.42 | -$276.39K | SELL-OPTIONS | 25.36% | 47.85K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | CHIEF EXECUTIVE OFFICER | 36.02K | $50.42 | -$1.62M | SELL-OPTIONS | 30.50% | 154.14K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, FINANCE & CFO | 13.80K | $50.42 | -$437.77K | SELL-OPTIONS | 17.91% | 90.89K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, CHIEF DEVELOPMENT OFFICER | 12.51K | $50.42 | -$369.96K | SELL-OPTIONS | 17.15% | 85.47K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, CHIEF SCIENTIFIC OFFICER | 11.57K | $50.42 | -$340.06K | SELL-OPTIONS | 17.59% | 77.32K | Jan 16 - Jan 17 | ||
Jan 18, 2024 | EVP, CHIEF BUSINESS OFFICER | 3.02K | $50.42 | -$102.04K | SELL-OPTIONS | ∞ | 1.64K | Jan 16 - Jan 17 | ||
Jan 17, 2024 | EVP, CHF CLINICAL DEVELOP OFCR | 0.00 | $43.05 | -$167.20K | SELL-OPTIONS | 0.00% | 38.17K | Jan 12 | ||
Jan 02, 2024 | EVP RESEARCH | 0.00 | $48.76 | -$77.17K | SELL-OPTIONS | 0.00% | 32.59K | Dec 28 | ||
Dec 28, 2023 | EVP CLO & GENERAL COUNSEL | 0.00 | $49.40 | -$85.86K | SELL-OPTIONS | 0.00% | 40.35K | Dec 26 | ||
Dec 28, 2023 | DIRECTOR | 0.00 | $48.91 | -$369.15K | SELL-OPTIONS | 0.00% | 82.59K | Dec 26 - Dec 28 | ||
Dec 28, 2023 | EVP, CHF CLINICAL DEVELOP OFCR | 0.00 | $49.40 | -$103.08K | SELL-OPTIONS | 0.00% | 36.05K | Dec 26 | ||
Dec 22, 2023 | EVP, CHIEF SCIENTIFIC OFFICER | 0.00 | $48.36 | -$46.36K | SELL-OPTIONS | 0.00% | 65.75K | Dec 20 - Dec 21 | ||
Dec 22, 2023 | EVP, CHIEF DEVELOPMENT OFFICER | 0.00 | $48.42 | -$22.95K | SELL-OPTIONS | 0.00% | 72.96K | Dec 20 - Dec 21 | ||
Dec 22, 2023 | CHIEF EXECUTIVE OFFICER | 0.00 | $48.36 | -$49.06K | SELL-OPTIONS | 0.00% | 118.11K | Dec 20 - Dec 21 | ||
Dec 18, 2023 | CHIEF EXECUTIVE OFFICER | 0.00 | $48.46 | -$53.86K | SELL-OPTIONS | 0.00% | 118.11K | Dec 14 | ||
Dec 18, 2023 | EVP, CHIEF DEVELOPMENT OFFICER | 0.00 | $48.46 | -$23.82K | SELL-OPTIONS | 0.00% | 72.96K | Dec 14 | ||
Dec 18, 2023 | EVP, CHIEF SCIENTIFIC OFFICER | 0.00 | $48.46 | -$50.74K | SELL-OPTIONS | 0.00% | 65.75K | Dec 14 | ||
Nov 17, 2023 | DIRECTOR | -2.00K | $50.00 | -$100.00K | SELL | -8.21% | 22.35K | Nov 15 | ||
Oct 18, 2023 | EVP RESEARCH | 73.00 | $47.95 | -$2.49K | SELL-OPTIONS | 0.22% | 32.59K | Oct 16 - Oct 17 | ||
Oct 16, 2023 | CHIEF EXECUTIVE OFFICER | -3.77K | $46.00 | -$173.42K | SELL | -3.09% | 118.11K | Oct 12 | ||
Sep 29, 2023 | EVP, CHIEF SCIENTIFIC OFFICER | -4.46K | $46.50 | -$207.39K | SELL | -6.35% | 65.75K | Sep 28 | ||
Sep 28, 2023 | DIRECTOR | -10.00K | $45.13 | -$451.27K | SELL | -10.80% | 82.59K | Sep 26 | ||
Sep 28, 2023 | DIRECTOR | -2.00K | $45.13 | -$90.25K | SELL | -7.59% | 24.35K | Sep 26 | ||
Aug 03, 2023 | DIRECTOR | -657.00 | $41.05 | -$26.97K | SELL | -4.93% | 12.68K | Aug 01 | ||
Jul 19, 2023 | DIRECTOR | 3.56K | $42.00 | -$149.31K | SELL-OPTIONS | 15.60% | 26.35K | Jul 17 - Jul 18 | ||
Jul 11, 2023 | CHIEF EXECUTIVE OFFICER | -18.65K | $42.25 | -$787.95K | SELL | -13.29% | 121.72K | Jul 07 | ||
May 24, 2023 | EVP CLO & GENERAL COUNSEL | -1.53K | $41.70 | -$63.68K | SELL | -3.65% | 40.35K | May 24 | ||
May 24, 2023 | CHIEF EXECUTIVE OFFICER | -4.93K | $40.14 | -$197.91K | SELL | -3.39% | 140.37K | May 22 | ||
Apr 19, 2023 | EVP, CORP AND DEVELOPMENT OPS | 1.20K | $36.50 | -$24.53K | SELL-OPTIONS | 3.41% | 36.53K | Apr 17 - Apr 18 | ||
Apr 19, 2023 | EVP, CHF GL PDT STR & OPER OFC | 3.08K | $36.50 | -$94.25K | SELL-OPTIONS | 14.53% | 24.31K | Apr 17 - Apr 18 | ||
Apr 19, 2023 | EVP, CHIEF BUSINESS OFFICER | 6.96K | $36.50 | -$141.63K | SELL-OPTIONS | 155.87% | 11.42K | Apr 17 - Apr 18 | ||
Feb 07, 2023 | EVP RESEARCH | 1.90K | $40.79 | -$74.03K | GRANT | 6.32% | 31.94K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP, CHF CLINICAL DEVELOP OFCR | 2.62K | $40.67 | -$57.46K | GRANT | 11.74% | 24.95K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP CLO & GENERAL COUNSEL | 1.90K | $40.86 | -$78.46K | GRANT | 4.79% | 41.58K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | CHIEF EXECUTIVE OFFICER | 24.44K | $40.69 | -$1.00M | GRANT | 20.22% | 145.31K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP, FINANCE & CFO | 2.06K | $40.59 | -$84.39K | GRANT | 2.81% | 75.50K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP, CHIEF DEVELOPMENT OFFICER | 1.90K | $40.66 | -$78.07K | GRANT | 2.70% | 72.39K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP, CHF GL PDT STR & OPER OFC | 2.69K | $40.66 | -$59.00K | GRANT | 14.51% | 21.23K | Feb 03 - Feb 06 | ||
Feb 07, 2023 | EVP, CHIEF SCIENTIFIC OFFICER | 1.80K | $40.57 | -$73.56K | GRANT | 2.65% | 69.65K | Feb 03 - Feb 06 | ||
Feb 02, 2023 | EVP CLO & GENERAL COUNSEL | -9.00K | $39.56 | -$356.07K | SELL | -18.49% | 39.68K | Jan 30 - Jan 31 | ||
Jan 19, 2023 | EVP RESEARCH | 10.15K | $39.74 | -$223.80K | SELL-OPTIONS | 51.02% | 30.04K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, CHF CLINICAL DEVELOP OFCR | 8.29K | $39.57 | -$188.05K | SELL-OPTIONS | 59.11% | 22.33K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP CLO & GENERAL COUNSEL | 14.04K | $39.49 | -$309.48K | SELL-OPTIONS | 40.51% | 48.68K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | CHIEF EXECUTIVE OFFICER | 32.20K | $39.49 | -$989.95K | SELL-OPTIONS | 36.32% | 120.86K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, FINANCE & CFO | 14.87K | $39.70 | -$328.72K | SELL-OPTIONS | 25.40% | 73.44K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, CHIEF DEVELOPMENT OFFICER | 14.11K | $39.57 | -$311.53K | SELL-OPTIONS | 25.03% | 70.48K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, CHF GL PDT STR & OPER OFC | 6.45K | $39.55 | -$148.22K | SELL-OPTIONS | 53.35% | 18.54K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, CHIEF SCIENTIFIC OFFICER | 12.44K | $38.89 | -$271.36K | SELL-OPTIONS | 22.45% | 67.86K | Jan 17 - Jan 18 | ||
Jan 19, 2023 | EVP, CHIEF BUSINESS OFFICER | 529.00 | $39.79 | -$14.92K | SELL-OPTIONS | 13.44% | 4.46K | Jan 17 - Jan 18 | ||
Jan 18, 2023 | DIRECTOR | -2.00K | $40.00 | -$80.00K | SELL | -8.07% | 22.79K | Jan 17 | ||
Sep 12, 2022 | EVP RESEARCH | -460.00 | $44.55 | -$20.49K | SELL | -2.26% | 19.89K | Sep 08 | ||
Aug 09, 2022 | EVP RESEARCH | -1.00 | $45.20 | -$45.20 | SELL | -0.00% | 20.35K | Aug 05 | ||
Jul 19, 2022 | DIRECTOR | 6.67K | $38.24 | -$50.98K | SELL-OPTIONS | 36.77% | 24.79K | Jul 15 | ||
Apr 25, 2022 | EVP RESEARCH | -378.00 | $44.15 | -$16.69K | SELL | -1.82% | 20.35K | Apr 21 | ||
Apr 14, 2022 | EVP CLO & GENERAL COUNSEL | -6.79K | $40.06 | -$272.06K | SELL | -16.43% | 34.54K | Apr 12 | ||
Apr 05, 2022 | CHIEF EXECUTIVE OFFICER | -355.00 | $37.49 | -$13.31K | SELL | -0.40% | 88.66K | Apr 01 | ||
Jul 19, 2021 | DIRECTOR | 4.33K | $35.30 | -$152.99K | SELL-OPTIONS | 31.18% | 18.23K | Jul 15 | ||
Jun 25, 2021 | DIRECTOR | 0.00 | $23.52 | -$426.60K | SELL-OPTIONS | 0.00% | 101.05K | Jun 23 | ||
Jun 17, 2021 | DIRECTOR | 0.00 | $22.97 | -$410.00K | SELL-OPTIONS | 0.00% | 31.68K | Jun 15 | ||
Mar 02, 2021 | CHIEF EXECUTIVE OFFICER | 11.00 | $49.41 | -$1.81K | ACQUISITION | 0.02% | 50.11K | Feb 26 - Mar 01 | ||
Jan 28, 2021 | EXEC CHAIRMAN THE BOARD | -28.33K | $63.74 | -$1.81M | SELL | -5.40% | 496.41K | Jan 26 | ||
Jan 27, 2021 | EVP & GENERAL COUNSEL | -5.32K | $63.50 | -$338.07K | SELL | -16.73% | 26.50K | Jan 25 | ||
Jan 25, 2021 | EXEC CHAIRMAN THE BOARD | -75.00K | $61.45 | -$4.61M | SELL | -13.10% | 497.50K | Jan 21 - Jan 22 | ||
Jan 15, 2021 | EVP, CHIEF DEVELOPMENT OFFC | -141.00 | $59.50 | -$8.39K | SELL | -0.46% | 30.31K | Jan 13 | ||
Jan 06, 2021 | EVP, RESEARCH | -195.00 | $55.99 | -$10.92K | SELL | -3.68% | 5.11K | Jan 05 | ||
Dec 28, 2020 | — | -10.00K | $60.00 | -$600.00K | SELL | -14.82% | 57.46K | Dec 23 | ||
Dec 17, 2020 | — | -40.41K | $49.80 | -$2.01M | SELL | -94.85% | 2.19K | Dec 15 - Dec 17 | ||
Dec 09, 2020 | — | -11.00K | $51.67 | -$568.35K | SELL | -1.69% | 640.97K | Dec 07 | ||
Dec 08, 2020 | — | 0.00 | $45.45 | -$266.29K | OPTION EXERCISE | 0.00% | 28.88K | Dec 04 | ||
Dec 08, 2020 | — | 0.00 | $45.45 | -$88.77K | OPTION EXERCISE | 0.00% | 32.48K | Dec 04 | ||
Dec 04, 2020 | — | 0.00 | $45.59 | -$80.76K | OPTION EXERCISE | 0.00% | 32.48K | Dec 02 | ||
Dec 04, 2020 | — | 0.00 | $45.59 | -$242.28K | OPTION EXERCISE | 0.00% | 28.88K | Dec 02 | ||
Nov 30, 2020 | — | 0.00 | $44.96 | -$220.70K | OPTION EXERCISE | 0.00% | 32.49K | Nov 25 | ||
Nov 30, 2020 | — | 0.00 | $44.96 | -$132.24K | OPTION EXERCISE | 0.00% | 652.41K | Nov 25 | ||
Nov 30, 2020 | — | 0.00 | $44.96 | -$121.35K | OPTION EXERCISE | 0.00% | 30.45K | Nov 25 | ||
Nov 30, 2020 | — | 0.00 | $44.96 | -$36.55K | OPTION EXERCISE | 0.00% | 67.46K | Nov 25 | ||
Nov 25, 2020 | — | 0.00 | $45.05 | -$152.24K | OPTION EXERCISE | 0.00% | 652.41K | Nov 23 - Nov 24 | ||
Nov 25, 2020 | — | 0.00 | $45.06 | -$241.91K | OPTION EXERCISE | 0.00% | 32.49K | Nov 23 - Nov 24 | ||
Nov 25, 2020 | — | 0.00 | $45.06 | -$135.65K | OPTION EXERCISE | 0.00% | 30.45K | Nov 23 - Nov 24 | ||
Nov 25, 2020 | — | 0.00 | $45.06 | -$40.57K | OPTION EXERCISE | 0.00% | 67.46K | Nov 23 - Nov 24 | ||
Nov 05, 2020 | — | 0.00 | $43.32 | -$103.55K | OPTION EXERCISE | 0.00% | 32.48K | Nov 03 | ||
Oct 22, 2020 | — | -2.89K | $46.86 | -$135.39K | SELL | -17.21% | 13.89K | Oct 20 |
FAQ
L'insider trading è legale?
L'insider trading è legale a condizione che gli insider segnalino le loro operazioni alla SEC. Il trading illegale di titoli si verifica quando l'insider viola un dovere fiduciario o non segnala le sue operazioni.
Quali sono alcuni esempi di manipolazione del mercato?
L'insider trading, gli schemi di pump and dump, il front running e i wash trade sono tutti esempi di manipolazione del mercato. Gli investitori che seguono i movimenti delle attività degli insider dovrebbero riflettere attentamente sul motivo per cui questi insider stanno negoziando le loro azioni prima di procedere.
Sfoglia insider trading su tutte le azioni.